Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Aug;8(4):329-333.
doi: 10.21037/gs.2017.11.03.

To each his own: a personalized vaccine for metastatic melanoma

Annalisa Chiocchetti  1 , Giuseppe Cappellano  2 , Umberto Dianzani  1
Affiliations
Editorial

To each his own: a personalized vaccine for metastatic melanoma

Annalisa Chiocchetti et al. Gland Surg. 2019 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
The picture depicts the biotechnological approach used to obtain personalized RNA-based vaccines for melanoma treatment (circle). The whole pattern of mutations inside the tumor mass, so-called the “mutanome”, is obtained by comparing DNA and RNA from both blood and bioptic sample. Based on the results, 10 neoantigens are selected for each patient if predicted to have high-affinity binding to the endogenous MHC class II and class-I molecules. The nucleic acid sequences are then engineered to produce RNAs encoding peptides corresponding to the selected neoantigens and injected into inguinal lymph nodes, where they will be translated into peptides, associated to MHC molecules and presented to T cells. This vaccination approach may work in synergy with checkpoint inhibitor-based immunotherapies (central panel), which may cooperate in unbreaking the response to vaccine neoantigens.
See this image and copyright information in PMC

Comment on

  • Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
    Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, Bukur V, Tadmor AD, Luxemburger U, Schrörs B, Omokoko T, Vormehr M, Albrecht C, Paruzynski A, Kuhn AN, Buck J, Heesch S, Schreeb KH, Müller F, Ortseifer I, Vogler I, Godehardt E, Attig S, Rae R, Breitkreuz A, Tolliver C, Suchan M, Martic G, Hohberger A, Sorn P, Diekmann J, Ciesla J, Waksmann O, Brück AK, Witt M, Zillgen M, Rothermel A, Kasemann B, Langer D, Bolte S, Diken M, Kreiter S, Nemecek R, Gebhardt C, Grabbe S, Höller C, Utikal J, Huber C, Loquai C, Türeci Ö. Sahin U, et al. Nature. 2017 Jul 13;547(7662):222-226. doi: 10.1038/nature23003. Epub 2017 Jul 5. Nature. 2017. PMID: 28678784

References

    1. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 2017;547:222-6. 10.1038/nature23003 - DOI - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. Available online: http://onlinelibrary.wiley.com/doi/10.3322/caac.21387/pdf - DOI - PubMed
    1. Ferlay J, Soerjomataram I, Ervik M, et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer, 2013. Available online: http://globocan.iarc.fr
    1. Achkar T, Tarhini AA. The use of immunotherapy in the treatment of melanoma. J Hematol Oncol 2017;10:88. 10.1186/s13045-017-0458-3 - DOI - PMC - PubMed
    1. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8. 10.1038/ni1102-991 - DOI - PubMed